891 related articles for article (PubMed ID: 12860947)
1. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
7. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
[TBL] [Abstract][Full Text] [Related]
8. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer.
Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Biondi E; Massa E; Mantovani G
Anticancer Res; 2004; 24(3b):1935-40. PubMed ID: 15274380
[TBL] [Abstract][Full Text] [Related]
13. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
16. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
17. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
18. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
